Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Shionogi & Co., Ltd.
  6. Summary
    4507   JP3347200002

SHIONOGI & CO., LTD.

(4507)
  Report
Delayed Japan Exchange  -  01:39 2022-07-05 am EDT
6985.00 JPY   +2.16%
11:53aShionogi & Co., Ltd. - Notice Regarding the Launch of the new SHIONOGI Group Brand
AQ
07/03SHIONOGI : Notice Regarding the Initiation of the Submission of Preparation Materials for a New Drug Application for S-217622, a Therapeutic Drug for COVID-19,
PU
07/01Shionogi & Co., Ltd. - Notice Regarding the Inclusion of Universal Antigen Vaccine Research into the Vaccine / New Modality Research and Development Project following a Public Solicitation by SCARDA
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Japan Exchange
06/29/2022 06/30/2022 07/01/2022 07/04/2022 07/05/2022 Date
6840(c) 6855(c) 6734(c) 6837(c) 6985 Last
1 147 900 1 307 100 1 235 500 1 151 300 1 059 800 Volume
-0.26% +0.22% -1.77% +1.53% +2.16% Change
More quotes
Estimated financial data (e)
Sales 2022 311 B 2 289 M 2 289 M
Net income 2022 106 B 784 M 784 M
Net cash position 2022 356 B 2 625 M 2 625 M
P/E ratio 2022 19,1x
Yield 2022 1,63%
Sales 2023 393 B 2 893 M 2 893 M
Net income 2023 140 B 1 032 M 1 032 M
Net cash position 2023 379 B 2 789 M 2 789 M
P/E ratio 2023 14,6x
Yield 2023 1,77%
Capitalization 2 061 B 15 190 M 15 190 M
EV / Sales 2022 5,49x
EV / Sales 2023 4,29x
Nbr of Employees 5 485
Free-Float 90,1%
More Financials
Company
Shionogi & Co., Ltd. specializes in development, manufacturing and marketing of pharmaceutical products. The group's activity is organized around 3 families of products: - prescription products: drugs for the treatment of cardiovascular and infectious diseases, diabetes, allergic reactions, etc.; - OTC products: analgesic products, vitamins and tonics, etc.; - diagnosis products: primarily for detection and... 
Read more
Sector
Pharmaceuticals
Calendar
08/01Earnings Release
More about the company
Ratings of Shionogi & Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about SHIONOGI & CO., LTD.
11:53aShionogi & Co., Ltd. - Notice Regarding the Launch of the new SHIONOGI Group Brand
AQ
07/03SHIONOGI : Notice Regarding the Initiation of the Submission of Preparation Materials for ..
PU
07/01Shionogi & Co., Ltd. - Notice Regarding the Inclusion of Universal Antigen Vaccine Rese..
AQ
06/28Shionogi Selected as a Member of the 'SOMPO Sustainability Index' for the 11th Consecut..
AQ
06/24Shionogi & Co., Ltd. - Notice of Disposal of Treasury Shares as Restricted Stock Compen..
AQ
06/24Shionogi & Co., Ltd. - Notice Regarding Acquisition and Cancellation of Treasury Stock
AQ
06/24Shionogi & Co., Ltd. - Notice Regarding Disposition of Treasury Stock by way of Third-p..
AQ
06/24Tech helps Japanese shares rise after solid Wall Street gains
RE
06/24Shionogi to Issue New Treasury Shares Under Compensation Plan; Shares Jump 5%
MT
06/24Shionogi Shareholders Approve Proposal to Acquire, Cancel Treasury Stock
MT
06/23Japan's Nikkei track Wall Street higher; tech stocks lead gains
RE
06/23Nikkei 225 Inches Up 0.1% on Strength in Retail, Transportation Sectors
MT
06/23SHIONOGI : Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
PU
06/23SHIONOGI : Notice Regarding Disposition of Treasury Stock by way of Third-party Allotment
PU
06/23SHIONOGI : Notice Regarding Acquisition and Cancellation of Treasury Stock
PU
More news
News in other languages on SHIONOGI & CO., LTD.
06/24Shionogi émettra de nouvelles actions propres dans le cadre d'un plan de rémunération ;..
06/23Le Nikkei 225 progresse de 0,1% grâce à la vigueur des secteurs de la vente au détail e..
06/23SHIONOGI & CO., LTD. (TSE : 4507) annonce un rachat d'actions pour 7.200.000 actions, repr..
06/23Shionogi & Co., Ltd. autorise un plan de rachat.
06/14Shionogi, GARDP et CHAI annoncent des accords de licence et de collaboration pour trait..
More news
Analyst Recommendations on SHIONOGI & CO., LTD.
More recommendations
Analysis
GSK to get $1.25 billion to settle HIV drug patent row with Gilead
Chart SHIONOGI & CO., LTD.
Duration : Period :
Shionogi & Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHIONOGI & CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 6 837,00 JPY
Average target price 7 944,62 JPY
Spread / Average Target 16,2%
EPS Revisions
Managers and Directors
Isao Teshirogi President, CEO & Representative Director
Motozo Shiono Director
Teppei Mogi Independent Outside Director
Keiichi Ando Independent Outside Director
Hiroshi Ozaki Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
SHIONOGI & CO., LTD.-17.12%15 015
JOHNSON & JOHNSON4.94%472 389
PFIZER, INC.-11.41%293 506
ELI LILLY AND COMPANY17.55%292 291
ROCHE HOLDING AG-15.48%272 104
ABBVIE INC.13.59%271 782